Some good stuff in there and shows how close some new products are to FDA approval.
What I particularly liked was the $40M+ spent on R&D for 2018.
That's what I want from MYX - a company that is not standing still and is looking to grow.
Yes they have been hit by a perfect storm with taking on Teva products as pricing was deflating, however, this will pass in time and recover.
Then when it does I can take my shares out of the bottom drawer and look at them again.
All this useless dribble about forward looking statements is just that dribble.
In an uncertain environment that is not in your control you can't give forward guidance - if you do and get it wrong then you will be slaughtered.
I would rather a company I am invested in to surprise to the upside not the other way (similar to MBL)
Ann: Mayne Pharma investor presentation to Goldmans conference, page-2
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.01 |
Change
-0.110(1.54%) |
Mkt cap ! $596.3M | |||
| Open | High | Low | Value | Volume |
| $7.14 | $7.17 | $7.00 | $608.8K | 85.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2971 | $7.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.06 | 427 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.02 |
Change
-0.110 ( 1.01 %) |
||||
| Open | High | Low | Volume | ||
| $7.14 | $7.18 | $7.00 | 10663 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| MYX (ASX) Chart |